KMDAKamada Ltd.

$520M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$45M+44.4% YoY

Gross Profit

$15M33.7% margin

Operating Income

$4M8.8% margin

Net Income

$3M6.5% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

+41.0%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$6M

Stock-Based Comp.

$218,000

Balance Sheet

Total Assets

$322M

Total Liabilities

$146M

Stockholders' Equity

$176M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$31M	+44.4%
Gross Profit	$15M	$7M	+131.9%
Operating Income	$4M	-$3M	+221.7%
Net Income	$3M	-$5M	+158.8%

KMDA Q4 2022 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena